Cardiology Plus最新文献

{"title":"The evolving landscape of transcatheter aortic valve intervention: a focus on native pure aortic regurgitation","authors":"Silvia Corona, T. Modine","doi":"10.1097/cp9.0000000000000091","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000091","url":null,"abstract":"","PeriodicalId":502215,"journal":{"name":"Cardiology Plus","volume":"2 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141383506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chinese expert consensus on anti-thrombotic therapy for pan-vascular diseases (2023 edition)","authors":"","doi":"10.1097/cp9.0000000000000079","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000079","url":null,"abstract":"Pan-vascular disease is a systemic condition characterized by vascular lesions, with atherosclerosis comprising 95% of cases, manifesting as coronary artery disease, cerebrovascular disease, peripheral artery disease, or combinations thereof, known as multivascular disease. In China, the burden of pan-vascular diseases is substantial, necessitating urgent improvements in patient prognosis. Despite being managed by different disciplines, pan-vascular diseases often share common risk factors and pathophysiological mechanisms, underscoring the need for standardized treatment strategies. Anti-thrombotic therapy for pan-vascular diseases primarily involves antiplatelet and anticoagulant therapy. Currently, there is a lack of unified guidance across various disciplines for patients with differing ischemic and bleeding risks and disease stages. Recognizing the pivotal role of standardized anti-thrombotic therapy in pan-vascular disease treatment, the Chinese College of Cardiovascular Physicians organized a consensus working group comprising 33 senior experts from cardiology, vascular surgery, neurology, and endocrinology. The “Chinese expert consensus on anti-thrombotic therapy for pan-vascular diseases (2023 Edition)” was developed based on specific treatment needs in China, incorporating published clinical research evidence, specialized guidelines and consensus, and recommendations from the consensus expert group. The primary aim of this consensus is to standardize the application of anti-thrombotic therapy in pan-vascular diseases, thereby optimizing clinical outcomes, improving patient prognosis, and mitigating the economic and societal burdens associated with pan-vascular disease.","PeriodicalId":502215,"journal":{"name":"Cardiology Plus","volume":" 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140218400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world effectiveness of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a retrospective, non-interventional cohort analysis","authors":"Michael Fu, A. Pivodic","doi":"10.1097/cp9.0000000000000077","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000077","url":null,"abstract":"\u0000 \u0000 Mineralocorticoid receptor antagonists (MRAs) have been shown in clinical trials to improve outcomes in heart failure with reduced ejection fraction (HFrEF). Yet, it is still uncertain how effective they are in real-world patients with HFrEF. This study aimed to investigate the association between MRAs and outcomes in the overall population and a propensity score-matched cohort, based on patient-level data from the Swedish Heart Failure Registry (SwedeHF).\u0000 \u0000 \u0000 \u0000 Patients diagnosed with HFrEF were included from the SwedeHF spanning from 2003 to 2020. Enrollment was based on medication dispensation within 3 months before and 6 months after the index date recorded in the register. Endpoints included all-cause mortality, cardiovascular death, and hospital re-admissions, tracked from the index date until censoring or occurrence of an event.\u0000 \u0000 \u0000 \u0000 Of 47,103 patients identified through the SwedeHF with HFrEF, 22,368 individuals were not treated with MRA (referred to as MRA naive patients), 21,893 were treated with MRA at a dosage of 25 mg, and 1,423 were treated with MRA at 50 mg once daily. In the overall cohort, the administration of MRA at 25 mg was associated with modest reductions in the risk of all-cause mortality (hazard ratio: 0.92 [0.89–0.95], P < 0.0001) and cardiovascular death (hazard ratio: 0.93 [0.89–0.98], P < 0.01) compared to the MRA naive group. However, both dosages of MRA (25 and 50 mg) were associated with a slight increase in the risk of hospital re-admissions due to heart failure 10% compared to MRA naive patients. These findings were consistent when examining a propensity score-matched cohort. Interaction analysis showed a significantly improved survival rate for patients receiving MRA at 25 mg compared to MRA naive individuals, particularly among those with an estimated glomerular rate ≥30 mL/min/1.73 m2 across all patients and in those aged 70 years and above.\u0000 \u0000 \u0000 \u0000 The administration of MRA treatment at 25 mg once daily was linked to a modestly improved survival in a real-life HFrEF population, with even more pronounced benefits observed within a specific subgroup. This finding highlights the importance of personalized medicine in providing customized therapeutic advantages.\u0000","PeriodicalId":502215,"journal":{"name":"Cardiology Plus","volume":"30 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140224993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pan-vascular disease: what we have done in the past and what we can do in the future?","authors":"Mingjen Wong, Yuxiang Dai, Junbo Ge","doi":"10.1097/cp9.0000000000000078","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000078","url":null,"abstract":"","PeriodicalId":502215,"journal":{"name":"Cardiology Plus","volume":"32 19","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140257559","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The predictive role of N-terminal pro-B-type natriuretic peptide in assessing outcomes for atrial fibrillation patients, with or without heart failure: a comprehensive systematic review and meta-analysis","authors":"Afina Syarah Lidvihurin, Yusuf Ananda Fikri","doi":"10.1097/cp9.0000000000000074","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000074","url":null,"abstract":"\u0000 \u0000 Brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are commonly used to predict clinical outcomes in patients with heart failure (HF). The prognostic role of BNP/NT-proBNP in patients with atrial fibrillation (AF) and comorbid HF is controversial. The current study aimed to understand the clinical importance of BNP/NT-proBNP measurement in predicting the outcomes of AF patients regardless of HF status.\u0000 \u0000 \u0000 \u0000 This is a systematic review and meta-analysis. A comprehensive literature search was conducted using PubMed, EBSCOHost, Cochrane, ScienceDirect, and ClinicalKey. Studies that reported all-cause mortality, stroke/systemic embolic events (SEE)/thromboembolic events (TE), major adverse cardiovascular events (MACE), and major bleeding were included in this study. All-cause mortality was the primary outcome. Studies that reported BNP data but not NT-proBNP were also included. BNP/NT-proBNP is categorized as high and low level based on the highest and lowest groups compared in the included studies.\u0000 \u0000 \u0000 \u0000 Sixteen studies (n = 45,400) were included in data synthesis: six were post hoc analysis of randomized controlled trials and the remaining were prospective cohort studies. The included studies were published between 2011 and 2022. The follow-up duration ranged from 1.0 to 5.2 years. High level of BNP/NT-proBNP was associated with a significantly increased risk of all-cause mortality (pooled hazard ratio [HR]: 2.26, 95% confidence interval [95% CI]: 1.98–2.56), stroke/SEE/TE (pooled HR: 2.45, 95% CI: 2.07–2.90), and MACE (pooled HR: 2.38, 95% CI: 1.90–2.99) in patients with AF; the pooled HR of major bleeding was 1.17 (95% CI: 1.01–1.36). Sensitivity analysis in patients with AF and HF produced similar results.\u0000 \u0000 \u0000 \u0000 BNP and NT-proBNP are strong predictors of clinical outcomes in patients with AF regardless of HF.\u0000","PeriodicalId":502215,"journal":{"name":"Cardiology Plus","volume":"39 6","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140259418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guideline-directed medical therapy in chemotherapy-induced cardiotoxicity and heart failure: current perspectives and practices","authors":"I. Cheang, Ziqi Chen, W. Yao, Haifeng Zhang, Xinli Li","doi":"10.1097/cp9.0000000000000076","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000076","url":null,"abstract":"Chemotherapy-induced cardiotoxicity and heart failure have become significant concerns in cancer treatment. Advancements in cancer therapies have increased survival rates, with consequent increase in the prevalence of chemotherapy-induced cardiotoxicity and subsequent heart failure. Guideline-directed medical therapy (GDMT) has emerged as a crucial approach for managing these conditions. GDMT encompasses evidence-based medications and interventions backed by clinical guidelines that aim to optimize the treatment and outcomes of heart failure. This review critically summarizes the existing evidence on the roles of GDMT in the management and prevention of chemotherapy-induced cardiotoxicity and heart failure.","PeriodicalId":502215,"journal":{"name":"Cardiology Plus","volume":"8 23","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140258454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing implementation of evidence-based heart failure therapies in clinical practice: vital to modern medicine","authors":"Michael Fu, Karl Swedberg","doi":"10.1097/cp9.0000000000000073","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000073","url":null,"abstract":"","PeriodicalId":502215,"journal":{"name":"Cardiology Plus","volume":"4 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140262733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"β-Arrestin-1 reduces acute myocardial infarction via promoting autophagy in cardiomyocytes","authors":"Mengzhen Liu, Hui Yan, Dan-Ni Zhu, Ni Kong, Qi Cao, Xiaoying Zhang, Wei Wei, Ping Ke, Xiongwen Chen, Chong Liu","doi":"10.1097/cp9.0000000000000064","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000064","url":null,"abstract":"β-Arrestins are key regulators of G protein–coupled receptor (GPCR) signaling. Through their function as scaffolding proteins, β-arrestins mediate a range of cellular signaling events. However, the role of β-arrestins during myocardial ischemia remains incompletely understood. In this study, we explored the regulatory effects of β-arrestin-1 on autophagy following myocardial infarction and sought to identify the underlying mechanism. Acute myocardial infarction was induced by permanent left anterior descending coronary artery ligation. Cardiac function was assessed using echocardiography. β-Arrestin-1, autophagy-related 5 (ATG5), and liver kinase B1 (LKB1) were overexpressed or knocked down using lentivirus-mediated transduction of the gene or short hairpin RNA (shRNA) in cultured primary cardiomyocytes. Oxygen-glucose deprivation (OGD) in cardiomyocytes was used to simulate cardiac ischemia in vitro. Autophagy and apoptosis were assessed by western blot, flow cytometry, and transmission electron microscopy. Cell survival and lactate dehydrogenase (LDH) release were evaluated using the respective kits. β-Arrestin-1 knockout (KO) increased myocardial infarction size, an effect that was associated with decreased autophagy and deterioration of cardiac function. The overexpression of β-arrestin-1 significantly increased autophagy levels and decreased cell apoptosis in cardiomyocytes exposed to OGD, whereas the knockdown of β-arrestin-1 exerted the opposite effect. The protective effect of β-arrestin-1 overexpression was abrogated by ATG5 knockdown. β-Arrestin-1 KO attenuated the myocardial infarction–induced phosphorylation of adenosine monophosphate (AMP)-activated protein kinase (AMPK). In cultured myocytes, the blockade of AMPK or the knockdown of LKB1 inhibited the β-arrestin-1–induced increase in the LC3-II/LC3-I ratio and beclin 1 expression levels and attenuated β-arrestin-1–mediated cardioprotective effects. Collectively, our findings suggested that β-arrestin-1 promotes cardiomyocyte survival under ischemic conditions via the regulation of LKB1/AMPK-dependent autophagy. These findings may be helpful in designing novel therapeutic strategies for myocardial ischemia.","PeriodicalId":502215,"journal":{"name":"Cardiology Plus","volume":"71 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139163338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between dapagliflozin and urinary albumin-to-creatinine ratio in patients with diabetes mellitus and cardiovascular disease: an observational study","authors":"Zejia Wu, Xuyu He, S. Xia, Xiaoju Xiao, Jiyan Chen, Liwen Li","doi":"10.1097/cp9.0000000000000065","DOIUrl":"https://doi.org/10.1097/cp9.0000000000000065","url":null,"abstract":"The potential impact of dapagliflozin on the urinary albumin-to-creatinine ratio (UACR) in patients with type 2 diabetes and cardiovascular disease remained inconclusive. We aimed to investigate the potential impact of dapagliflozin on the UACR in patients with diabetes mellitus complicated with cardiovascular disease. This is a single-center prospective observation study. Diabetic patients with cardiovascular disease were recruited at authors’ center (both outpatients and inpatients) during a period from June 2019 to November 2020. The study subjects were grouped into a dapagliflozin group (receiving dapagliflozin for at least 6 consecutive months) and a non-sodium-glucose cotransporter 2 inhibitors (SGLT2i) group (not receiving dapagliflozin or any other SGLT2i). LgUACR change at 6 months from the baseline were compared between the two groups. A total of 57 patients were enrolled during a period from June 2019 to November 2020: 35 in the dapagliflozin group versus 22 in the non-SGLT2i group. LgUACR change from the baseline was −0.07 in the dapagliflozin group, and 0.17 in the non-SGLT2i group (P = 0.021). Dapagliflozin was associated with a decrease in UACR in the univariate regression analysis but not in the analysis of covariance. Dapagliflozin may be associated with a decrease in the UACR in patients with diabetes mellitus and cardiovascular disease. In view of the limited sample size, further investigation is needed to verify these findings.","PeriodicalId":502215,"journal":{"name":"Cardiology Plus","volume":"94 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139222782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}